Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 5/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412889 | 1.00 | P2RX7 (0.69) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL1412865 | 0.89 | P2RX7 (0.58) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL3473781 | 0.89 | P2RX7 (0.60) | P2RX7ABCB11THRB | |
| SCHEMBL1412856 | 0.87 | P2RX7 (0.52) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL5838150 | 0.87 | P2RX7 (0.52) | P2RX7ABCB11 | |
| SCHEMBL1412926 | 0.86 | P2RX7 (0.64) | P2RX7ABCB11THRB | |
| SCHEMBL1415262 | 0.85 | P2RX7 (0.62) | P2RX7ABCB11THRB | |
| SCHEMBL1412884 | 0.85 | P2RX7 (0.62) | P2RX7ABCB11THRB | |
| SCHEMBL1412887 | 0.85 | P2RX7 (0.49) | P2RX7ABCB11THRBTHRA | |
| SCHEMBL5839014 | 0.85 | P2RX7 (0.49) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | claimed |
| EP-1768965-A1 | METHOD FOR PREPARING 5-¬4-(2-HYDROXY-ETHYL)-3,5-DIOXO-4,5-DIHYDRO-3H-¬1,2,4|-TRIAZIN-2-YL|BENZAMIDE DERIVATIVES WITH P2X7 INHIBITING ACTIVITY BY REACTION OF THE DERIVATIVE UNSUBSTITUTED IN 4-POSITION OF THE TRIAZINE WITH AN OXIRAN IN THE PRESENCE OF A LEWIS ACID | Pfizer Products Incorporated (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006003513-A1 | METHOD FOR PREPARING 5-`4-(2-HYDROXY-ETHYL)-3,5-DIOXO-4,5-DIHYDRO-3H-`1,2,4!-TRIAZIN-2-YL!BENZAMIDE DERIVATIVES WITH P2X7 INHIBITING ACTIVITY BY REACTION OF THE DERIVATIVE UNSUBSTITUTED IN 4-POSITION OF THE TRIAZINE WITH AN OXIRAN IN THE PRESENCE OF A LEWIS ACID | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20050288288-A1 | Methods for preparing P2X7 inhibitors | PFIZER INC. | 2005-12-29 | — | — | US | claimed |
| EP-1448535-B1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1768965-A1 | METHOD FOR PREPARING 5-¬4-(2-HYDROXY-ETHYL)-3,5-DIOXO-4,5-DIHYDRO-3H-¬1,2,4|-TRIAZIN-2-YL|BENZAMIDE DERIVATIVES WITH P2X7 INHIBITING ACTIVITY BY REACTION OF THE DERIVATIVE UNSUBSTITUTED IN 4-POSITION OF THE TRIAZINE WITH AN OXIRAN IN THE PRESENCE OF A LEWIS ACID | Pfizer Products Incorporated (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1763353-A1 | COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X<sb>7</sb> RECEPTOR | Warner-Lambert Company LLC (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2006-03-16 | — | — | US | disclosed |
| US-20060018904-A1 | Combination therapies utilizing benzamide inhibitors of the P2X7 receptor | WARNER-LAMBERT COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2006003517-A1 | COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006003513-A1 | METHOD FOR PREPARING 5-`4-(2-HYDROXY-ETHYL)-3,5-DIOXO-4,5-DIHYDRO-3H-`1,2,4!-TRIAZIN-2-YL!BENZAMIDE DERIVATIVES WITH P2X7 INHIBITING ACTIVITY BY REACTION OF THE DERIVATIVE UNSUBSTITUTED IN 4-POSITION OF THE TRIAZINE WITH AN OXIRAN IN THE PRESENCE OF A LEWIS ACID | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288288-A1 | Methods for preparing P2X7 inhibitors | PFIZER INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1448535-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003042191-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 866/4885THRB 1200/4885 |
| US-20060018904-A1 | Combination therapies utilizing benzamide inhibitors of the P2X7 receptor | CSF3R, CSF1R, IL1R1 | P2RX7 72/4885ABCB11 753/4885THRB 2124/4885 |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 443/4885THRB 772/4885 |
| US-20050288288-A1 | Methods for preparing P2X7 inhibitors | P2RX7, P2RX1, P2RX2 | P2RX7 1/4885ABCB11 266/4885THRB 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.